A case of iatrogenic immunodeficiency-associated colonic lymphoma complicating ulcerative colitis

Suzuki, Kazushi; Ohe, Rintaro; Kabasawa, Takanobu; Aung, Naing Ye; Yano, Mitsuhiro; Katsumi, S; Yanagiya, Ryo; Yamamoto, Masakazu; Toubai, Tomomi; Ishizawa, Kenichi; Yamakawa, Mitsunori

doi:10.1186/s13000-020-00954-8

Cited by 5 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, lymphoma is a relatively rare complication (0.02–3.1%) [ 2 , 3 ]. We searched “Behçets disease” and “lymphoma” in PubMed, and there were 7 available studies published in English from 2000 to 2020 (Table 1 ) [ 1 , 7 , 8 , 9 , 10 , 11 , 12 ]. All cases had been treated with immunosuppressants such as colchicine, steroids, azathioprine, and diaminodiphenyl sulfone.…”

Section: Discussionmentioning

confidence: 99%

“…Lymphoma that arises in patients who have been treated with immunosuppressants is now classified as Oii-LPDs [ 6 ], and the DLBCL type is the most common type. In particular, Oii-DLBCL associated with rheumatoid arthritis is most common [ 10 ], but other autoimmune diseases including ulcerative colitis [ 11 ], are also associated with Oii-DLBCL. Among Oii-LPDs, CI-associated Oii-LPD cases are uncommon, and their profiles or prognosis are not fully understood.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders, Diffuse Large B-Cell Lymphoma Type, in a Patient with Behçet’s Disease Treated with Cyclosporine A

et al. 2020

Self Cite

View full text Add to dashboard Cite

A 40-year-old man had been treated for Behçet’s disease (BD) with cyclosporine A (CsA) for 14 years. He presented multiple lymphadenopathies with fever. Histological examination of surgical biopsy showed other iatrogenic immunodeficiency-associated lymphoproliferative disorders, diffuse large B-cell lymphoma type with positivity for Epstein-Barr virus encoding RNA-1 (EBER-1). BCL2-IgH, BCL6-IgH, and MYC-IgH translocations were not detected. CsA was stopped, and R-CHOP therapy was initiated. However, his lymphoma was chemotherapy resistant and rapidly progressed. To the best of our knowledge, this is the first case of diffuse large B-cell lymphoma that occurred in a BD patient treated with CsA reported in English. Both BD and CsA are associated with the pathogenesis of lymphoma. We also describe extremely rare cases in the form of a literature review.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders, Diffuse Large B-Cell Lymphoma Type, in a Patient with Behçet’s Disease Treated with Cyclosporine A

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Paraffin‐embedded thymic tissue sections from patients diagnosed with FTH‐RA ( n = 4) and FTH‐MG ( n = 8) were assessed. A paraffin‐embedded colonic lymphoma section ( n = 1) 13 was used as a positive control for EBER‐ISH, which was performed with a BOND‐III (Leica Biosystems) Autostainer using BOND EBER Probe (Leica Biosystems).…”

Section: Methodsmentioning

confidence: 99%

Pathogenesis of follicular thymic hyperplasia associated with rheumatoid arthritis

Ohe

Yang

Yamashita

et al. 2022

Pathology International

Self Cite

View full text Add to dashboard Cite

Lymphoproliferative disorders may occur in patients with rheumatoid arthritis (RA) who are treated with methotrexate. However, follicular thymic hyperplasia (FTH) associated with RA (FTH‐RA) is generally not considered a lymphoproliferative disorder. To investigate the pathogenesis of FTH‐RA, we examined 12 cases of FTH involving thymic enlargement, four of FTH involving RA and eight of FTH involving myasthenia gravis (MG). Increased numbers and larger germinal center (GC) size were observed in FTH‐RA group. The percentage of distorted GCs was 13.3% in FTH‐RA group and 3.25% in FTH associated with MG (FTH‐MG) group. A greater meshwork of follicular dendritic cells was observed in the GCs of FTH‐RA group. Positive indices of CD27+ cells and PD‐1+ cells per GC in FTH‐RA group were significantly higher than those in FTH‐MG group, though positive indices of CD68+ cells and CD163+ cells were similar. Myoid cell proliferation, as evaluated by α‐SMA, tenascin‐C, and l‐caldesmon expression, was significantly increased in the FTH‐RA group compared with the FTH‐MG group. These results suggest that FTH should be considered in patients with RA treated with methotrexate. The pathogenesis of FTH‐RA includes GC expansion and increased numbers of memory B cells, follicular helper T cells, and myoid cells, indicating humoral immunity activation.

show abstract

“…Moreover, there are many reports in the literature involving CD patients who have been diagnosed with different types of lymphoma. In 60% of cases, lymphomas occur in the small and large intestines [18,[79][80][81]. However, it should be noted that information regarding the safety of IBD therapy in those with a history of lymphoma is scarce.…”

Section: The Role Of Ibd Therapy In Increasing the Risk Of Cancer Rec...mentioning

confidence: 99%

The Complex Relationship between Mechanisms Underlying Inflammatory Bowel Disease, Its Treatment, and the Risk of Lymphomas: A Comprehensive Review

Stasik,

Filip

2024

IJMS

View full text Add to dashboard Cite

Patients with inflammatory bowel disease may be at higher risk of developing lymphomas and other cancers of the gastrointestinal tract. In addition, there may be a link between the use of thiopurines or anti-tumor necrosis factor drugs (anti-TNF) and these pathologies. The treatment of patients with Crohn’s disease who have previously been diagnosed with lymphoma is a challenge for gastroenterologists. In this report, we examine important clinical issues related to the treatment of patients with inflammatory bowel disease with active lymphoma, as well as of patients with hematological cancer history. In this discussion, we take into account most of the available treatments for inflammatory bowel disease, as well as the impact of chronic inflammation and viral infections. In addition, we try to find common ground for the development of lymphoproliferative disorders and autoimmune diseases. Patients with inflammatory bowel disease may be at higher risk of developing lymphomas and other cancers of the gastrointestinal tract. Chronic inflammatory processes and viral infections play an important role in carcinogenesis. In addition, there may be a link between the use of thiopurines or anti-TNF drugs and these pathologies. A significant risk of the development of lymphoma in people undergoing each therapy should be considered, and it should be estimated how much greater this risk will be in patients with a history of lymphoproliferative disorders. The following review is an attempt to answer which therapy would be the most appropriate for patients with Crohn’s disease and a history of lymphoma treatment. A lack of clear guidelines creates great challenges for doctors.

show abstract

A case of iatrogenic immunodeficiency-associated colonic lymphoma complicating ulcerative colitis

Cited by 5 publications

References 13 publications

Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders, Diffuse Large B-Cell Lymphoma Type, in a Patient with Behçet’s Disease Treated with Cyclosporine A

Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders, Diffuse Large B-Cell Lymphoma Type, in a Patient with Behçet’s Disease Treated with Cyclosporine A

Pathogenesis of follicular thymic hyperplasia associated with rheumatoid arthritis

The Complex Relationship between Mechanisms Underlying Inflammatory Bowel Disease, Its Treatment, and the Risk of Lymphomas: A Comprehensive Review

Contact Info

Product

Resources

About